# AstraZeneca PLC (AZN)

Source: https://www.quantisnow.com/company/AZN
Generated: 2026-11-22T19:50:26.854Z

- Ticker: AZN
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2026
- SEC CIK: 0000901832
- Website: astrazeneca.com

## About

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

## Latest AZN news and filings

- 2026-11-19 12:00 UTC [Sonesitatug vedotin granted Priority Review in the US for 2nd and later-line treatment of patients with CLDN18.2-positive advanced gastric/GEJ cancers](https://www.quantisnow.com/insight/sonesitatug-vedotin-granted-priority-review-in-the-us-for-2nd-6799796)
- 2026-11-16 12:21 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6792197)
- 2026-11-16 12:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6792185)
- 2026-11-16 12:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6792166)
- 2026-11-16 11:52 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6792092)
- 2026-11-13 23:39 UTC [Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer](https://www.quantisnow.com/insight/perioperative-imfinzi-durvalumab-approved-in-the-us-in-novel-regimen-6791653)
- 2026-11-13 19:30 UTC [FDA Approval for KLYGEFA issued to ALEXION PHARM](https://www.quantisnow.com/insight/fda-approval-for-klygefa-issued-to-alexion-pharm-6790183)
- 2026-11-10 20:20 UTC [AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US](https://www.quantisnow.com/insight/astrazeneca-awards-16-million-for-programs-to-improve-access-to-6783654)
- 2026-11-10 11:44 UTC [SEC Form 4] [Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-sharma-mani-was-granted-1-units-of-ordinary-shares-6782618)
- 2026-11-09 13:00 UTC [Gabelli Releases Agenda for 8th Annual Healthcare Symposium](https://www.quantisnow.com/insight/gabelli-releases-agenda-for-8th-annual-healthcare-symposium-6780377)
- 2026-11-02 15:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6766611)
- 2026-11-02 15:23 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6766601)
- 2026-10-30 11:36 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6764567)
- 2026-10-30 11:00 UTC [Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product](https://www.quantisnow.com/insight/enhertu-wins-2026-international-prix-galien-award-for-best-biotechnology-6764451)
- 2026-10-30 11:00 UTC [Earnings Date] [AstraZeneca results: 9M and Q3 2026](https://www.quantisnow.com/insight/astrazeneca-results-9m-and-q3-2026-6764450)
- 2026-10-30 01:10 UTC [2027 Could Finally Be the Year Cancer Is on the Ropes!](https://www.quantisnow.com/insight/2027-could-finally-be-the-year-cancer-is-on-the-6764235)
- 2026-10-28 12:00 UTC [AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing](https://www.quantisnow.com/insight/astrazeneca-and-mark-paul-gosselaar-launch-meet-your-mark-to-raise-6760583)
- 2026-10-27 10:51 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6758366)
- 2026-10-27 07:30 UTC [Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer](https://www.quantisnow.com/insight/enhertu-approved-in-the-eu-as-adjuvant-treatment-for-patients-6758161)
- 2026-10-26 17:12 UTC [Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades](https://www.quantisnow.com/insight/billions-in-new-plants-trillions-in-potential-obesity-drug-revenue-over-6757389)
- 2026-10-26 12:00 UTC [Gabelli To Host 8th Annual Healthcare Symposium](https://www.quantisnow.com/insight/gabelli-to-host-8th-annual-healthcare-symposium-6757032)
- 2026-10-25 15:35 UTC [Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01](https://www.quantisnow.com/insight/sonesitatug-vedotin-reduced-the-risk-of-death-by-42-in-6756748)
- 2026-10-25 15:30 UTC [TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO](https://www.quantisnow.com/insight/tagrisso-osimertinib-plus-savolitinib-reduced-the-risk-of-disease-progression-6756747)
- 2026-10-24 14:35 UTC [IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial](https://www.quantisnow.com/insight/imfinzi-durvalumab-plus-tarlatamab-dlle-reduced-the-risk-of-death-by-6756731)
- 2026-10-24 14:30 UTC [Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer](https://www.quantisnow.com/insight/perioperative-imfinzi-durvalumab-plus-neoadjuvant-enfortumab-vedotin-reduced-risk-of-6756729)
- 2026-10-22 12:10 UTC [ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations](https://www.quantisnow.com/insight/zegfrovy-sunvozertinib-now-available-in-the-us-for-patients-with-6754521)
- 2026-10-22 11:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6754342)
- 2026-10-20 13:00 UTC [TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week](https://www.quantisnow.com/insight/tezspire-positive-results-from-phase-iii-crossing-trial-in-eosinophilic-6751721)
- 2026-10-08 13:00 UTC [SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology](https://www.quantisnow.com/insight/sophia-genetics-and-myriad-genetics-announce-new-collaboration-to-advance-6741361)
- 2026-10-08 13:00 UTC [Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology](https://www.quantisnow.com/insight/myriad-genetics-and-sophia-genetics-announce-new-collaboration-to-advance-6741341)
- 2026-10-08 11:12 UTC [SEC Form 4] [SEC Form 4 filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-4-filed-by-astrazeneca-plc-6741030)
- 2026-10-05 16:01 UTC [AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts](https://www.quantisnow.com/insight/astrazeneca-opens-new-global-strategic-rd-center-in-kendall-square-6736439)
- 2026-10-05 11:35 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6735926)
- 2026-10-05 11:00 UTC [AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics](https://www.quantisnow.com/insight/astrazeneca-completes-2-billion-equity-investment-in-summit-therapeutics-6735860)
- 2026-10-02 10:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6733423)
- 2026-10-02 06:30 UTC [Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway](https://www.quantisnow.com/insight/summit-therapeutics-announces-clinical-trial-collaboration-with-astrazeneca-and-daiichi-6733303)
- 2026-10-02 06:30 UTC [Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types](https://www.quantisnow.com/insight/daiichi-sankyo-and-astrazeneca-enter-into-clinical-trial-collaboration-with-6733302)
- 2026-10-01 15:40 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6731984)
- 2026-10-01 15:32 UTC [SEC Form 6-K] [SEC Form 6-K filed by AstraZeneca PLC](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-astrazeneca-plc-6731968)
- 2026-09-29 16:12 UTC [Public Offering] [High-Stakes October has these Biotechs Entering Crucial Stretch](https://www.quantisnow.com/insight/high-stakes-october-has-these-biotechs-entering-crucial-stretch-6728952)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AZN
- Earnings history: https://www.quantisnow.com/earnings/AZN
- Dividend history: https://www.quantisnow.com/dividends/AZN
- Insider transactions: https://www.quantisnow.com/insiders/AZN
- Options chain: https://www.quantisnow.com/options/AZN
- SEC 8-K filings only: https://www.quantisnow.com/company/AZN/8-k
- RSS and alerts for AZN: https://www.quantisnow.com/docs/rss-feeds.md
